PE83999A1 - Azetidinas - Google Patents
AzetidinasInfo
- Publication number
- PE83999A1 PE83999A1 PE1998000589A PE00058998A PE83999A1 PE 83999 A1 PE83999 A1 PE 83999A1 PE 1998000589 A PE1998000589 A PE 1998000589A PE 00058998 A PE00058998 A PE 00058998A PE 83999 A1 PE83999 A1 PE 83999A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- optionally replaced
- halogen
- compound
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DERIVADO DE AZETIDINILPROPILPIPERIDINA DE FORMULA (I), DONDE A ES CO, SO2 o CH2; Ar1 ES FENILO OPCIONALMENTE SUSTITUIDO POR HALOGENO, ALCOXI C1-C6, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDOS POR HALOGENOS; X1 ES CICLOALQUILO C3-C7 OPCIONALMENTE SUSTITUIDO POR ALQUILO C1-C4, CICLOALQUILO C3-C7, ALCOXILO C1-C4; ARILO O ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO POR FLUOR, COOH, CO2(ALQUILO C1-C4), ENTRE OTROS; X ES UN ENLACE DIRECTO O NR1; R ES SO2-ARILO, SO2(ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO POR HALOGENO); R1 ES H, ALQUILO C1-C6 FENILO, OPCIONALMENTE SUSTITUIDO POR HALOGENO; Y ES O, NCO(ALQUILO C1-C6), NCO2(ALQUILO C1-C6) OPCIONALMENTE SUSTITUIDOS POR HALOGENO, ENTRE OTROS; CUANDO R ES UN GRUPO DE FORMULA (a, b), X NO ES NR1. UN COMPUESTO PREFERIDO ES (+)-3-(R)-1-BENZOIL-3-(3-[3-(4-TERC-BUTOXICARBONILPIPERAZIN-1-IL)AZETIDIN-1-IL]PROPIL)-3-(3,4-DICLOROFENILO)PIPERIDINA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA SOBRE UNA TAQUIQUININA QUE ACTUA EN EL RECEPTOR HUMANO NK1, NK2 o NK3; PUDIENDO SER UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD INFLAMATORIA COMO ARTRITIS, PSORIASIS, ASMA O ENFERMEDAD INFLAMATORIA DEL INTESTINO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9714129.5A GB9714129D0 (en) | 1997-07-04 | 1997-07-04 | Azetidines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE83999A1 true PE83999A1 (es) | 1999-09-11 |
Family
ID=10815370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000589A PE83999A1 (es) | 1997-07-04 | 1998-07-01 | Azetidinas |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6262046B1 (es) |
| EP (1) | EP1023285A1 (es) |
| JP (1) | JP2000511207A (es) |
| KR (1) | KR20010015532A (es) |
| CN (1) | CN1261887A (es) |
| AP (1) | AP1110A (es) |
| AR (1) | AR013171A1 (es) |
| AU (1) | AU726708B2 (es) |
| BG (1) | BG103992A (es) |
| BR (1) | BR9810544A (es) |
| CA (1) | CA2294193A1 (es) |
| CO (1) | CO4950604A1 (es) |
| DZ (1) | DZ2550A1 (es) |
| EA (1) | EA002773B1 (es) |
| GB (1) | GB9714129D0 (es) |
| GT (1) | GT199800106A (es) |
| HN (1) | HN1998003689A (es) |
| HR (1) | HRP20000002B1 (es) |
| HU (1) | HUP0002330A3 (es) |
| ID (1) | ID24090A (es) |
| IL (1) | IL133433A0 (es) |
| IS (1) | IS5295A (es) |
| MA (1) | MA26519A1 (es) |
| NO (1) | NO996115L (es) |
| NZ (1) | NZ501715A (es) |
| OA (1) | OA11236A (es) |
| PA (1) | PA8454601A1 (es) |
| PE (1) | PE83999A1 (es) |
| PL (1) | PL338004A1 (es) |
| SK (1) | SK182799A3 (es) |
| TN (1) | TNSN98127A1 (es) |
| TR (1) | TR200000025T2 (es) |
| TW (1) | TW492960B (es) |
| UY (1) | UY25079A1 (es) |
| WO (1) | WO1999001451A1 (es) |
| ZA (1) | ZA985875B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9714129D0 (en) | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
| WO1999019297A1 (en) * | 1997-10-15 | 1999-04-22 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| FR2787449B3 (fr) | 1998-12-15 | 2001-01-12 | Sanofi Sa | Derives de 3-phenyl-2,6-dioxopiperidin-3-yl propionamide et leur procede de preparation |
| FR2787448B3 (fr) | 1998-12-18 | 2001-01-12 | Sanofi Sa | Ester d'alkyle inferieur de l'acide 3-(3,4-dihalogenophenyl) -2,6-dioxopiperidine3-propionique et son mode de preparation |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| JP4660199B2 (ja) * | 2002-12-23 | 2011-03-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用 |
| TW200508221A (en) | 2003-06-13 | 2005-03-01 | Astrazeneca Ab | New azetidine compounds |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| FR2876689B1 (fr) * | 2004-10-14 | 2008-02-22 | Aventis Pharma Sa | Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide |
| NZ556628A (en) * | 2005-03-08 | 2009-09-25 | Janssen Pharmaceutica Nv | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| US8106208B2 (en) | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| ATE517100T1 (de) | 2007-08-07 | 2011-08-15 | Hoffmann La Roche | Pyrrolidinarylether als nk3-rezeptorantagonisten |
| US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
| CN107614504B (zh) | 2015-06-23 | 2019-12-24 | 卫材R&D管理有限公司 | 甲酰胺化合物的晶体 |
| RU2750539C2 (ru) | 2017-02-08 | 2021-06-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция для лечения опухоли |
| AU2018269996A1 (en) | 2017-05-16 | 2019-11-21 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676055B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5625060A (en) | 1991-05-03 | 1997-04-29 | Elf Sanofi | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present |
| TW432061B (en) | 1994-08-09 | 2001-05-01 | Pfizer Res & Dev | Lactams |
| FR2729951B1 (fr) * | 1995-01-30 | 1997-04-18 | Sanofi Sa | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant |
| GB9600235D0 (en) | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
| GB9601697D0 (en) * | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
| GB9714129D0 (en) | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
-
1997
- 1997-07-04 GB GBGB9714129.5A patent/GB9714129D0/en active Pending
-
1998
- 1998-06-01 TW TW087108533A patent/TW492960B/zh active
- 1998-06-30 HN HN1998003689A patent/HN1998003689A/es unknown
- 1998-07-01 IL IL13343398A patent/IL133433A0/xx unknown
- 1998-07-01 WO PCT/EP1998/004177 patent/WO1999001451A1/en not_active Ceased
- 1998-07-01 HU HU0002330A patent/HUP0002330A3/hu unknown
- 1998-07-01 HR HR970497A patent/HRP20000002B1/xx not_active IP Right Cessation
- 1998-07-01 PL PL98338004A patent/PL338004A1/xx unknown
- 1998-07-01 NZ NZ501715A patent/NZ501715A/en unknown
- 1998-07-01 KR KR1020007000013A patent/KR20010015532A/ko not_active Abandoned
- 1998-07-01 UY UY25079A patent/UY25079A1/es not_active IP Right Cessation
- 1998-07-01 AU AU88062/98A patent/AU726708B2/en not_active Ceased
- 1998-07-01 TR TR2000/00025T patent/TR200000025T2/xx unknown
- 1998-07-01 EA EA199901102A patent/EA002773B1/ru not_active IP Right Cessation
- 1998-07-01 MA MA25151A patent/MA26519A1/fr unknown
- 1998-07-01 DZ DZ980160A patent/DZ2550A1/xx active
- 1998-07-01 BR BR9810544-2A patent/BR9810544A/pt not_active IP Right Cessation
- 1998-07-01 CA CA002294193A patent/CA2294193A1/en not_active Abandoned
- 1998-07-01 CN CN98806898A patent/CN1261887A/zh active Pending
- 1998-07-01 EP EP98939619A patent/EP1023285A1/en not_active Withdrawn
- 1998-07-01 SK SK1827-99A patent/SK182799A3/sk unknown
- 1998-07-01 US US09/423,771 patent/US6262046B1/en not_active Expired - Fee Related
- 1998-07-01 PE PE1998000589A patent/PE83999A1/es not_active Application Discontinuation
- 1998-07-01 ID IDW20000006A patent/ID24090A/id unknown
- 1998-07-01 JP JP11506382A patent/JP2000511207A/ja active Pending
- 1998-07-02 AP APAP/P/1998/001291A patent/AP1110A/en active
- 1998-07-02 AR ARP980103228A patent/AR013171A1/es not_active Application Discontinuation
- 1998-07-02 PA PA19988454601A patent/PA8454601A1/es unknown
- 1998-07-03 CO CO98037815A patent/CO4950604A1/es unknown
- 1998-07-03 ZA ZA9805875A patent/ZA985875B/xx unknown
- 1998-07-10 TN TNTNSN98127A patent/TNSN98127A1/fr unknown
- 1998-07-14 GT GT199800106A patent/GT199800106A/es unknown
-
1999
- 1999-12-10 IS IS5295A patent/IS5295A/is unknown
- 1999-12-10 NO NO996115A patent/NO996115L/no not_active Application Discontinuation
- 1999-12-13 BG BG103992A patent/BG103992A/xx unknown
- 1999-12-15 OA OA9900282A patent/OA11236A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE83999A1 (es) | Azetidinas | |
| ATE103604T1 (de) | Substituierte 5-((tetrazolyl)alkenyl>-imidazole. | |
| PE29798A1 (es) | Acetidinas | |
| DE69034103D1 (de) | Imidazoalkensäure | |
| DE69616480D1 (de) | Piperidinderivate als neurokininantagonisten | |
| DE69724777D1 (de) | Pentafluorobenzensulfonamiden und analoge | |
| PE20040512A1 (es) | Compuesto de pirazol-pirimidina anilina | |
| EP0948327A4 (en) | ANTIDIABETIC AGENTS | |
| ES2163638T3 (es) | Nuevas n-(1-alquil-5-fenil-2,3,4,5-tetrahidro-1h-benzo(b)(1,5)diacepin-3-il)acetamidas. | |
| EP0786995A4 (es) | ||
| SE9703414D0 (sv) | New compounds | |
| PT669920E (pt) | 3-aminoalquilamino-1,2-benzoxazoles substituidos ecompostos relacionados | |
| FI905481A0 (fi) | Substituerade n-(imidazolyl) -alkylalaninderivat. | |
| PE16399A1 (es) | Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores | |
| DE69626981D1 (de) | N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide | |
| PE75199A1 (es) | Derivado de quinolina util como antagonista de neuroquinina | |
| ES2172029T3 (es) | 3-amino-1-cianofenil-uracilos. | |
| ATE196899T1 (de) | N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5- benzodiazepin-3-yl)-3-amide | |
| ES2194102T3 (es) | Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas. | |
| ATE213731T1 (de) | Chinoxalinderivate und ihre therapeutische verwendbarkeit | |
| FR2707990B1 (fr) | Nouvelles nitrones utilisables pour le piégeage des radicaux libres. | |
| ES2165410T3 (es) | Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen. | |
| UY26329A1 (es) | Antagonistas de los receptores de vitronectina | |
| PE16499A1 (es) | Compuestos heterociclicos de guanidinilamino utiles como agonistas de alfa-2 adrenoreceptores | |
| ATE113949T1 (de) | Alpha-adrenergische rezeptorantagonisten. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |